DPP4 inhibitors and cardiovascular outcomes: safety on heart failure.

about

Pharmacokinetic drug evaluation of empagliflozin plus linagliptin for the treatment of type 2 diabetes.DPP-4 inhibitors and heart failure: a potential role for pharmacogenomics.

P2860

Q47293312-E4822406-B8C3-4A00-9862-B4EAD2FA0C81 Q48229830-923E5DDE-B771-4216-AEE0-1C52F7040023

P2860

DPP4 inhibitors and cardiovascular outcomes: safety on heart failure.

Item

http://www.wikidata.org/entity/Q38833312

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

DPP4 inhibitors and cardiovascular outcomes: safety on heart failure.

@en

type

Item

label

DPP4 inhibitors and cardiovascular outcomes: safety on heart failure.

@en

prefLabel

DPP4 inhibitors and cardiovascular outcomes: safety on heart failure.

@en

P1476

DPP4 inhibitors and cardiovascular outcomes: safety on heart failure.

@en

P2093

Aditya Goud

http://www.w3.org/2001/XMLSchema#string

CHanukya Dahagam

http://www.w3.org/2001/XMLSchema#string

Chang Xia

http://www.w3.org/2001/XMLSchema#string

Jason D'Souza

http://www.w3.org/2001/XMLSchema#string

Sanjay Rajagopalan

http://www.w3.org/2001/XMLSchema#string

Xiaoquan Rao

http://www.w3.org/2001/XMLSchema#string

P2860

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies

Dipeptidyl Peptidase 4 Inhibitors and the Risk of Cardiovascular Disease in Patients with Type 2 Diabetes: A Tale of Three Studies

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

Effects of intensive glucose lowering in type 2 diabetes

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

Physical activity and reduced occurrence of non-insulin-dependent diabetes mellitus.

Insulin resistance in chronic heart failure.

Sulfonylurea use and incident cardiovascular disease among patients with type 2 diabetes: prospective cohort study among women.

Functional class in patients with heart failure is associated with the development of diabetes.

P2888

s10741-017-9617-4

P304

299-304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10741-017-9617-4

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Jixin Zhong

P577

2017-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28417296

http://www.w3.org/2001/XMLSchema#string

P932

5491332

http://www.w3.org/2001/XMLSchema#string

DPP4 inhibitors and cardiovascular outcomes: safety on heart failure.

about

P2860

P2860

DPP4 inhibitors and cardiovascular outcomes: safety on heart failure.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P932